Description: Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. Its lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. The company was founded in 2014 and is headquartered in San Diego, California.
Home Page: www.dermatarx.com
DRMA Technical Analysis
3525 Del Mar Heights Road
San Diego,
CA
92130
United States
Phone:
858 800 2543
Officers
| Name | Title |
|---|---|
| Mr. Gerald T. Proehl | Founder, Pres, CEO & Chairman |
| Mr. David F. Hale | Co-Founder & Lead Independent Director |
| Ms. Kyri K. Van Hoose CPA, M.B.A. | Sr. VP & CFO |
| Dr. Christopher J. Nardo M.P.H., Ph.D. | Sr. VP & Chief Devel. Officer |
| Mr. Sean Proehl | Sr. Director of Legal & Bus. Devel. |
| Dr. Maria Bedoya Toro Munera M.B.A., Ph.D. | Sr. VP of Regulatory Affairs & Quality Assurance |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3031 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-08-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |